Global G-CSF Biosimilars Market Size study, by Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies) and Regional Forecasts 2018-2025

February 2019 | 200 pages | ID: GD7B9A792C9EN
Bizwit Research & Consulting LLP

Abstracts

Global G-CSF Biosimilars Market to reach USD XX billion by 2025.

Global G-CSF Biosimilars Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The G-CSF Biosimilars Market is continuously growing across the world over the coming years. Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000. GCSF stimulates granulocyte production in BM suppressed by chemotherapy and radiotherapy and reduces infections in cancer patients. It can induce terminal maturation of myeloid leukemia cells, resulting in complete hematologic and cytologic remission, and can suppress self-renewal. It is useful in patients with AIDS or leukemic relapse after allogeneic BM transplantation. Increasing aging population, growing incidence of chronic diseases and rising healthcare expenditure are the substantial driving factors of the market across the globe. In addition, growing acceptance due to their cost-effectiveness is also boosting the market growth over the upcoming years. Furthermore, patent expiry of biologic products is the major factor which creating numerous opportunity in the market over the coming years. However, complications associated with manufacturing of G-CSF biosimilars are the factors which limiting the market growth of G-CSF Biosimilars over the coming years. The regional analysis of Global G-CSF Biosimilars Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World.

The major market player included in this report are:

• Pfizer
• Novartis
• Roche
• Merck & Co.
• Sanofi
• Johnson & Johnson
• Gilead Science
• GlaxoSmithKline
• AbbVie
• Amgen
• AstraZeneca
• Bayer

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

• Human Growth Hormone
• Erythropoietin
• Monoclonal Antibodies
• Insulin
• Interferon
• Granulocyte-Colony Stimulating Factor

By Application:

• Blood Disorders
• Oncology Diseases
• Chronic and Autoimmune Diseases
• Growth Hormone Deficiencies

By Regions:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• Asia Pacific
• China
• India
• Japan
• Latin America
• Brazil
• Mexico
• Rest of the World

Furthermore, years considered for the study are as follows:

• Historical year – 2015, 2016
• Base year – 2017
• Forecast period – 2018 to 2025

Target Audience of the Global G-CSF Biosimilars Market in Market Study:

• Key Consulting Companies & Advisors
• Large, medium-sized, and small enterprises
• Venture capitalists
• Value-Added Resellers (VARs)
• Third-party knowledge providers
• Investment bankers
• Investors

Contents

CHAPTER 1. EXECUTIVE SUMMARY

1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
  1.3.1. G-CSF Biosimilars Market, by Type, 2015-2025 (USD Billion)
  1.3.2. G-CSF Biosimilars Market, by Application, 2015-2025 (USD Billion)
  1.3.3. G-CSF Biosimilars Market, by Region, 2015-2025 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption

CHAPTER 2. G-CSF BIOSIMILARS MARKET DEFINITION AND SCOPE

2.1. Objective of the Study
2.2. Market Definition & Scope
  2.2.1. Industry Evolution
  2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

CHAPTER 3. G-CSF BIOSIMILARS MARKET DYNAMICS

3.1. See Saw Analysis
  3.1.1. Market Drivers
  3.1.2. Market Challenges
  3.1.3. Market Opportunities

CHAPTER 4. G-CSF BIOSIMILARS MARKET INDUSTRY ANALYSIS

4.1. Porter’s 5 Force Model
  4.1.1. Bargaining Power of Buyers
  4.1.2. Bargaining Power of Suppliers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
  4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
  4.2.1. Political Scenario
  4.2.2. Economic Scenario
  4.2.3. Social Scenario
  4.2.4. Technological Scenario
4.3. Value Chain Analysis
  4.3.1. Supplier
  4.3.2. Manufacturers/Service Provider
  4.3.3. Distributors
  4.3.4. End-Users
4.4. Key Buying Criteria
4.5. Regulatory Framework
4.6. Cost Structure Analysis
  4.6.1. Raw Material Cost Analysis
  4.6.2. Manufacturing Cost Analysis
  4.6.3. Labor Cost Analysis
4.7. Investment Vs Adoption Scenario
4.8. Analyst Recommendation & Conclusion

CHAPTER 5. G-CSF BIOSIMILARS MARKET, BY TYPE

5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. G-CSF Biosimilars Market, Sub Segment Analysis
  5.4.1. Human Growth Hormone
    5.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.2. Erythropoietin
    5.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.3. Monoclonal Antibodies
    5.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.4. Insulin
    5.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.5. Interferon
    5.4.5.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.5.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.6. Granulocyte-Colony Stimulating Factor
    5.4.6.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.6.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 6. G-CSF BIOSIMILARS MARKET, BY APPLICATION

6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. G-CSF Biosimilars Market, Sub Segment Analysis
  6.4.1. Blood Disorders
    6.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.2. Oncology Diseases
    6.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.3. Chronic and Autoimmune Diseases
    6.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.4. Growth Hormone Deficiencies
    6.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 7. G-CSF BIOSIMILARS MARKET, BY REGIONAL ANALYSIS

7.1. G-CSF Biosimilars Market, Regional Market Snapshot (2015-2025)
7.2. North America G-CSF Biosimilars Market Snapshot
  7.2.1. U.S.
    7.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.2.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.2.1.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.2.2. Canada
    7.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.2.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.2.2.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3. Europe G-CSF Biosimilars Market Snapshot
  7.3.1. U.K.
    7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.1.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.3.2. Germany
    7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.2.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.3.3. France
    7.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.3.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.3.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.3.4. Rest of Europe
    7.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.4.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.4.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4. Asia G-CSF Biosimilars Market Snapshot
  7.4.1. China
    7.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.1.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.4.2. India
    7.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.2.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.4.3. Japan
    7.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.3.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.3.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.4.4. Rest of Asia Pacific
    7.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.4.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.4.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5. Latin America G-CSF Biosimilars Market Snapshot
  7.5.1. Brazil
    7.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.5.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.5.1.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.5.2. Mexico
    7.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.5.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.5.2.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6. Rest of The World
  7.6.1. South America
    7.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.6.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.6.1.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.6.2. Middle East and Africa
    7.6.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.6.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.6.2.3. Application breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Company Market Share (Subject to Data Availability)
8.2. Top Market Strategies
8.3. Company Profiles
  8.3.1. Pfizer
    8.3.1.1. Overview
    8.3.1.2. Financial (Subject to Data Availability)
    8.3.1.3. Product Summary
    8.3.1.4. Recent Developments
  8.3.2. Novartis
  8.3.3. Roche
  8.3.4. Merck & Co.
  8.3.5. Sanofi
  8.3.6. Johnson & Johnson
  8.3.7. Gilead Science
  8.3.8. GlaxoSmithKline
  8.3.9. AbbVie
  8.3.10. Amgen
  8.3.11. AstraZeneca
  8.3.12. Bayer

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process
  9.1.1. Data Mining
  9.1.2. Analysis
  9.1.3. Market Estimation
  9.1.4. Validation
  9.1.5. Publishing
  9.1.6. Research Assumption